Psyence Biomedical Ltd. PBM
2.51 USD -0.30 (-10.68%)
Regular-session close
2.61 +0.10 +3.98%
After hours · Nov 17, 6:13 PM ET
2.51 Day range 2.99
1.92 52-week range 110.16
- YTD
- -91.47%
- 1 year
- -97.78%
News
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…benzinga.com Psyence Biomedical Completes Its Additional Investment In PsyLabs Of $2,599,896 Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today announced that both milestones attached to its backstop subscription commitment in Psyence Labs Ltd. ("PsyLabs")
globenewswire.com Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that both milestones attached to its backstop subscription…
globenewswire.com Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program Partnership intended to establish a…
globenewswire.com Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a…
globenewswire.com Psyence BioMed Announces Strategic Ibogaine Investment Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential…
globenewswire.com Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine development Positioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion…
benzinga.com Modular Medical Secures National PBM Contract For Pivot Insulin Pump Commercial-stage medical device manufacturer Modular Medical Inc. (NASDAQ:MODD) recently signed a significant contract with a national U.S. pharmacy benefit manager (PBM).
globenewswire.com Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built Company says growing federal commitment to…
businesswire.com Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) technologies, has been selected to support the administration of Scripius' commercial, Medicare, and…
globenewswire.com Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived…
newsfilecorp.com Pacific Bay Adopts Semi-Annual Reporting Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Pacific Bay Minerals Ltd. (TSXV: PBM) ("Pacific Bay" or the "Company") reports that the Company is adopting semi-annual financial…
globenewswire.com Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a…
feeds.benzinga.com PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.
globenewswire.com Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic…
globenewswire.com Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply Company highlights global leadership in GMP ibogaine manufacturing and commitment to…
thenewswire.com Aurwest Resources Announces Execution of Definitive Agreement on Weaver Lake Gold Project Calgary, Alberta – TheNewswire - April 14, 2026 – Aurwest Resources Corporation (“ Aurwest ” or the “ Company ”) ( CSE: AWR ) is pleased to announce that the Company has entered into a Definitive…
globenewswire.com Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine…
defenseworld.net Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM) Psyence Biomedical (NASDAQ: PBM - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies…
globenewswire.com Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone “The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig “The strongest companies are built on the right foundations long before their…
globenewswire.com Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine…
